Study shows Ostinol (ZyCal Bioceuticals) improves pain and stiffness in Osteoarthritis

Results of the first double-blind, placebo-controlled study evaluating the benefits of Ostinol (cyplexinol), from ZyCal Bioceuticals, in alleviating symptoms of Osteoarthritis shows that this nutritional supplement decreases pain and stiffness, and offers an increase in quality of life as compared to placebo. Cyplexinol is a biologically active protein complex consisting of bone morphogenetic proteins which stimulate bone and cartilage growth and fight inflammation. In the study 87 participants diagnosed with moderate-to-severe Osteoarthritis joint pain in a weight-bearing joint (the hip or knee) were randomized to receive a daily dose of either 150 mg of cyplexinol or placebo for 12 weeks.

During the study, a significant improvement (decrease) in pain, stiffness, and QOL was observed on the WOMAC subscales for the treatment group. The change in the group's mean scores reached significance in as early as 1 week. The results were published in Integrative Medicine: A Clinician's Journal. See: "Evaluating Clinical Response and Activity of Cyplexinol Osteoinductive Proteins in Osteoarthritis of the Hip and Knee: A Randomized, Controlled Trial." Richard Garian and James J. Scaffid. Integrative Medicine, Vol. 12, No. 2, April 2013